This page shows the latest trial failure news and features for those working in and with pharma, biotech and healthcare.
Bispecific antibody fails in non-small cell lung cancer trial. Bintrafusp alfa – the novel immunotherapy at the centre of a major alliance between GlaxoSmithKline (GSK) and Merck KGaA – has failed in ... Although GSK has not issued a press release
While we are disappointed that ADAMTS-5 inhibition by GLPG1972 proved not to make a difference in this trial, we want to express our gratitude to all participating patients and investigators,” ... Gilead can pin some of its hopes on another of
Biogen maintained that the failure of aducanumab in a second trial – ENGAGE – was most likely due to the fact that there weren’t a sufficient number of patients receiving enough exposure
Biogen maintained that failure in the second trial of aducanumab was likely due to the fact that there weren’t a sufficient number of patients receiving enough exposure to the higher
The EMPEROR-Reduced trial evaluated SGLT2 inhibitor Jardiance (empagliflozin) in patients with heart failure with reduced ejection fraction (HFrEF). ... Aside from the EMPEROR-Reduced trial, Boehringer/Lilly is also investigating Jardiance as a treatment
Drug reduced rate of cardiovascular deaths and hospitalisations. Bayer and Merck &Co have unveiled the data from their phase 3 trial of vericiguat in high-risk heart failure, backing up a ... The patients in the trial were well treated, with more than a
More from news
Approximately 26 fully matching, plus 76 partially matching documents found.
Moreover, published literature tends to catalogue successful clinical trials, but data from an unsuccessful trial – provided its failure did not result from safety issues – can still help make the case for ... Yet it seems that numerous archives of
A subsequent leak about the apparent failure of remdesivir in a Chinese trial then dampened expectations again. ... A clinical trial of Regeneron’s drug is scheduled to start in June.
The result of this consultation is Havas Lynx Group’s latest white paper‘Patient Centricity on Trial’. ... This kind of simple, practical question can be the difference between success and failure of a clinical trial, and is usually only raised by
Avoiding failure. By taking this approach to research, it's possible to avoid one of the major pitfalls facing pharma today – the high cost of late-stage trial failure. ... Particularly when we have high failure rates in late stages in clinical studies,
Multiple studies have pegged the probability of clinical trial success at between 13-20 per cent. ... This estimate has remained constant over decades. Among the major reasons for clinical trial failure are problems that rest squarely in the domain of
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
This is one of the highest clinical trial failure rates in healthcare. ... Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose
For example, poor dose selection in phase II is frequently cited as one of the top causes of late-stage clinical trial failure. ... As such, it has prioritised phase II/III adaptive trial designs as well as other types of study.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...